Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001127855-13-000456
Filing Date
2013-06-21
Accepted
2013-06-21 14:11:45
Documents
10
Period of Report
2013-02-28

Document Format Files

Seq Description Document Type Size
1 NAPRODIS 10Q, 02.28.13 naprodis10q022813.htm 10-Q 365148
2 NAPRODIS 10Q, CERTIFICATION 302, CEO naprodisexh31_1.htm EX-31.1 10119
3 NAPRODIS 10Q, CERTIFICATION 302, CFO naprodisexh31_2.htm EX-31.2 10089
4 NAPRODIS 10Q, CERTIFICATION 906, CEO/CFO naprodisexh32.htm EX-32.1 5867
  Complete submission text file 0001127855-13-000456.txt   2382389

Data Files

Seq Description Document Type Size
5 napr-20130228_cal.xml EX-101.CAL 19672
6 napr-20130228_def.xml EX-101.DEF 8363
7 napr-20130228.xml EX-101.INS 483173
8 napr-20130228_lab.xml EX-101.LAB 67346
9 napr-20130228_pre.xml EX-101.PRE 56300
10 napr-20130228.xsd EX-101.SCH 11104
Mailing Address 13250 GREGG STREET SUITE F POWAY CA 92064
Business Address 13250 GREGG STREET SUITE F POWAY CA 92064 (858) 486-8655
Naprodis, Inc. (Filer) CIK: 0001313938 (see all company filings)

EIN.: 330903494 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 333-122009 | Film No.: 13926636
SIC: 2834 Pharmaceutical Preparations